1. Home
  2. MIRM vs FICO Comparison

MIRM vs FICO Comparison

Compare MIRM & FICO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIRM
  • FICO
  • Stock Information
  • Founded
  • MIRM 2018
  • FICO 1956
  • Country
  • MIRM United States
  • FICO United States
  • Employees
  • MIRM N/A
  • FICO N/A
  • Industry
  • MIRM Biotechnology: Pharmaceutical Preparations
  • FICO Business Services
  • Sector
  • MIRM Health Care
  • FICO Consumer Discretionary
  • Exchange
  • MIRM Nasdaq
  • FICO Nasdaq
  • Market Cap
  • MIRM 1.9B
  • FICO 46.1B
  • IPO Year
  • MIRM 2019
  • FICO 1987
  • Fundamental
  • Price
  • MIRM $40.80
  • FICO $1,951.79
  • Analyst Decision
  • MIRM Strong Buy
  • FICO Buy
  • Analyst Count
  • MIRM 11
  • FICO 12
  • Target Price
  • MIRM $58.55
  • FICO $2,173.58
  • AVG Volume (30 Days)
  • MIRM 438.4K
  • FICO 191.9K
  • Earning Date
  • MIRM 05-07-2025
  • FICO 04-29-2025
  • Dividend Yield
  • MIRM N/A
  • FICO N/A
  • EPS Growth
  • MIRM N/A
  • FICO 21.78
  • EPS
  • MIRM N/A
  • FICO 21.79
  • Revenue
  • MIRM $336,888,000.00
  • FICO $1,775,435,000.00
  • Revenue This Year
  • MIRM $29.51
  • FICO $17.79
  • Revenue Next Year
  • MIRM $20.27
  • FICO $15.57
  • P/E Ratio
  • MIRM N/A
  • FICO $89.61
  • Revenue Growth
  • MIRM 80.76
  • FICO 14.49
  • 52 Week Low
  • MIRM $23.83
  • FICO $1,105.65
  • 52 Week High
  • MIRM $54.23
  • FICO $2,402.52
  • Technical
  • Relative Strength Index (RSI)
  • MIRM 45.27
  • FICO 58.18
  • Support Level
  • MIRM $38.22
  • FICO $1,791.23
  • Resistance Level
  • MIRM $39.87
  • FICO $1,971.12
  • Average True Range (ATR)
  • MIRM 2.27
  • FICO 85.93
  • MACD
  • MIRM 0.23
  • FICO 10.93
  • Stochastic Oscillator
  • MIRM 61.83
  • FICO 94.99

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About FICO Fair Isaac Corproation

Founded in 1956, Fair Isaac Corporation is a leading applied analytics company. Fair Isaac is primarily known for its FICO credit scores, which is a widely used industry benchmark to determine the creditworthiness of an individual consumer. The firm's credit scores business accounts for most of the firm's profits and consists of business-to-business and business-to-consumer services. In addition to scores, Fair Isaac also sells software primarily to financial institutions for areas such as analytics, decision-making, customer workflows, and fraud.

Share on Social Networks: